Gary E. Aspnes

1.1k total citations
16 papers, 367 citations indexed

About

Gary E. Aspnes is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Organic Chemistry. According to data from OpenAlex, Gary E. Aspnes has authored 16 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 4 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Organic Chemistry. Recurrent topics in Gary E. Aspnes's work include Diabetes Treatment and Management (4 papers), Receptor Mechanisms and Signaling (4 papers) and Lipid metabolism and biosynthesis (2 papers). Gary E. Aspnes is often cited by papers focused on Diabetes Treatment and Management (4 papers), Receptor Mechanisms and Signaling (4 papers) and Lipid metabolism and biosynthesis (2 papers). Gary E. Aspnes collaborates with scholars based in United States, Australia and Germany. Gary E. Aspnes's co-authors include Liuqing Wei, Nathan E. Genung, Leonard Buckbinder, Benjamin D. Stevens, Daniel P. Walker, Angel Guzmán-Pérez, Matt Griffor, Hong Wang, Jeanne S. Chang and Peter C. Bonnette and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Chemical Biology.

In The Last Decade

Gary E. Aspnes

16 papers receiving 359 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary E. Aspnes United States 8 186 134 62 47 38 16 367
Dennis Norman United Kingdom 10 142 0.8× 90 0.7× 38 0.6× 30 0.6× 53 1.4× 11 382
Jim D. Durbin United States 11 239 1.3× 96 0.7× 63 1.0× 37 0.8× 109 2.9× 16 445
Ingrid A. Stock United States 10 305 1.6× 199 1.5× 57 0.9× 14 0.3× 66 1.7× 14 519
Matthew Plant United States 15 525 2.8× 125 0.9× 55 0.9× 68 1.4× 26 0.7× 24 789
Dominic E. A. Brittain United States 8 210 1.1× 126 0.9× 65 1.0× 31 0.7× 13 0.3× 12 396
Paul A. Tuthill United States 9 167 0.9× 149 1.1× 19 0.3× 33 0.7× 15 0.4× 14 371
Denise Wilcox United States 11 239 1.3× 57 0.4× 87 1.4× 18 0.4× 43 1.1× 18 472
John M. Pritchard United Kingdom 11 191 1.0× 81 0.6× 12 0.2× 44 0.9× 9 0.2× 17 367
Yuzhe Xing Canada 7 195 1.0× 165 1.2× 144 2.3× 22 0.5× 34 0.9× 7 496
Afshin Bahador United States 10 314 1.7× 47 0.4× 14 0.2× 41 0.9× 42 1.1× 19 496

Countries citing papers authored by Gary E. Aspnes

Since Specialization
Citations

This map shows the geographic impact of Gary E. Aspnes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary E. Aspnes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary E. Aspnes more than expected).

Fields of papers citing papers by Gary E. Aspnes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary E. Aspnes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary E. Aspnes. The network helps show where Gary E. Aspnes may publish in the future.

Co-authorship network of co-authors of Gary E. Aspnes

This figure shows the co-authorship network connecting the top 25 collaborators of Gary E. Aspnes. A scholar is included among the top collaborators of Gary E. Aspnes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary E. Aspnes. Gary E. Aspnes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Nar, Herbert, Gisela Schnapp, Holger Klein, et al.. (2025). Engineering oxypurinol-responsive riboswitches based on bacterial xanthine aptamers for gene expression control in mammalian cell culture. Nucleic Acids Research. 53(5). 1 indexed citations
2.
Aspnes, Gary E., Steven B. Coffey, Anne‐Marie Dechert‐Schmitt, et al.. (2023). Small molecule inhibitors of PCSK9. SAR investigations of head and amine groups. Bioorganic & Medicinal Chemistry Letters. 92. 129394–129394. 1 indexed citations
3.
Aspnes, Gary E., Scott W. Bagley, Steven B. Coffey, et al.. (2023). 6-Azaspiro[2.5]octanes as small molecule agonists of the human glucagon-like peptide-1 receptor. Bioorganic & Medicinal Chemistry Letters. 94. 129454–129454. 4 indexed citations
4.
Aspnes, Gary E., Elnaz Menhaji‐Klotz, Markus Boehm, et al.. (2021). Discovery and evaluation of non-basic small molecule modulators of the atypical chemokine receptor CXCR7. Bioorganic & Medicinal Chemistry Letters. 50. 128320–128320. 2 indexed citations
5.
Londregan, Allyn T., Gary E. Aspnes, Chris Limberakis, et al.. (2018). Discovery of N-(piperidin-3-yl)-N-(pyridin-2-yl)piperidine/piperazine-1-carboxamides as small molecule inhibitors of PCSK9. Bioorganic & Medicinal Chemistry Letters. 28(23-24). 3685–3688. 10 indexed citations
6.
Herr, Michael, Gary E. Aspnes, Shawn Cabral, et al.. (2018). Route Selection and Optimization in the Synthesis of Two Imidazopyridine Inhibitors of DGAT-2. Organic Process Research & Development. 22(3). 360–367. 6 indexed citations
7.
Tu, Meihua, Benjamin D. Stevens, Jianwei Bian, et al.. (2014). Identification of a novel conformationally constrained glucagon receptor antagonist. Bioorganic & Medicinal Chemistry Letters. 24(3). 839–844. 16 indexed citations
8.
Nolte, Whitney M., Jean‐Philippe Fortin, Benjamin D. Stevens, et al.. (2014). A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification. Nature Chemical Biology. 10(8). 629–631. 66 indexed citations
9.
Genung, Nathan E., Liuqing Wei, & Gary E. Aspnes. (2014). Regioselective Synthesis of 2H-Indazoles Using a Mild, One-Pot Condensation–Cadogan Reductive Cyclization. Organic Letters. 16(11). 3114–3117. 94 indexed citations
10.
Guzmán-Pérez, Angel, Jeffrey A. Pfefferkorn, Benjamin D. Stevens, et al.. (2013). The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus. Bioorganic & Medicinal Chemistry Letters. 23(10). 3051–3058. 35 indexed citations
11.
Tse, Kathy W.K., May Dang-Lawson, Angel Guzmán-Pérez, et al.. (2012). Small molecule inhibitors of the Pyk2 and FAK kinases modulate chemoattractant-induced migration, adhesion and Akt activation in follicular and marginal zone B cells. Cellular Immunology. 275(1-2). 47–54. 21 indexed citations
12.
Bahnck, Kevin B., Yong Tao, Andrei Shavnya, et al.. (2012). Efficient Synthesis of 4-Amino-2-methoxy-7,8-dihydropyrido[4,3-d]pyrimidin-5-ones: Practical Access to a Novel Chemotype in the Development of DGAT-1 Inhibitors. Synthesis. 44(20). 3152–3157. 2 indexed citations
13.
Dow, Robert L., Gary E. Aspnes, E. Michael Gibbs, et al.. (2011). Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core. Bioorganic & Medicinal Chemistry Letters. 21(20). 6122–6125. 12 indexed citations
14.
15.
Han, Seungil, Anil Mistry, Jeanne S. Chang, et al.. (2009). Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design. Journal of Biological Chemistry. 284(19). 13193–13201. 86 indexed citations
16.
Bi, F. Christopher, Gary E. Aspnes, Angel Guzmán-Pérez, & Daniel P. Walker. (2008). Novel syntheses of 3-anilino-pyrazin-2(1H)-ones and 3-anilino-quinoxalin-2-(1H)-ones via microwave-mediated Smiles rearrangement. Tetrahedron Letters. 49(11). 1832–1835. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dennis Norman Breakdown of academic impact, for papers by Jim D. Durbin Breakdown of academic impact, for papers by Ingrid A. Stock Breakdown of academic impact, for papers by Matthew Plant Breakdown of academic impact, for papers by Dominic E. A. Brittain Breakdown of academic impact, for papers by Paul A. Tuthill Breakdown of academic impact, for papers by Denise Wilcox Breakdown of academic impact, for papers by John M. Pritchard Breakdown of academic impact, for papers by Yuzhe Xing Breakdown of academic impact, for papers by Afshin Bahador
Rankless by CCL
2026